AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05536973 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ADVM-022
Description: A single IVT injection of 6E10 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
Study NCT05096364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK111/Placebo
Description: After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
Study NCT05096364 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AK111/Placebo
Description: After loading dose, investigational drug was administered subcutaneously up to 60 weeks.
Study NCT04757025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography
Description: In 27 patients ventilation will be guided with an Electrical Impedance Tomography system
Study NCT04757025 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral arterial Saturation
Description: The ventilation of 27 patients will be guided by Peripheral arterial Saturation alone
Study NCT06196268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core strengthening exercise
Description: CSE will constitute of abdominal hollowing, Side Bridge, supine extension bridge, straight leg rise from prone, alternate arm and leg raise from quadruped, and prone bridge
Study NCT06196268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: Pilates includes hundreds, one leg stretch, shoulder bridge, hip twist, scissors, side kicks
Study NCT04928612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-1018
Description: CBP-1018 for injection, IV infusion
Study NCT06468085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: premixed Bioceramic NeoPUTTY®
Description: Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
Study NCT06468085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine™
Description: Pulpotomy procedure will be performed after hemostasis followed by covering pulp stump with Premixed Bioceramic or Biodentine™ according to the corresponding group then final composite restoration will be applied. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
Study NCT06468085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: Root canal treatment will be performed to the control group followed by composite restoration. clinical evaluation will be done at baseline, 3, 6, 9 and 12 months.
Study NCT05823311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib, tislelizumab, gemcitabine and cisplatin
Description: Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
Study NCT05823311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine and cisplatin
Description: Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
Study NCT04974164 — intervention group
Intervention type: BIOLOGICAL
Intervention: Inactivated COVID-19 Vaccine
Description: Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen
Study NCT05705739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrolaminar block
Description: curved probe will be placed 1-1.5 cm lateral to the target spinous process after identification of the lamina, the needle will be advanced caudally until it contacts the lamina
Study NCT05705739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: curved probe will be placed 2-3 cm lateral to the spine using a sagittal approach at the level of T8. After identification of erector spinae muscle and transverse processes, the needle will be inserted deeply into the erector spinae muscle.
Study NCT06409481 — intervention group
Intervention type: DRUG
Intervention: Antineoplastic Agents
Description: small-molecule kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, cytotoxic drugs, and other therapeutics
Study NCT06487897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimal laser keratoplasty
Description: Laser
Study NCT05138705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Virus Split Vaccine
Description: 0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains
Study NCT05953519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
Study NCT05282537 — intervention group
Intervention type: BEHAVIORAL
Intervention: In person academic activities
Description: All participants will perform academic activities in person from March to December, 2022
Study NCT04610801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray
Description: Randomized to placebo and Xlear
Study NCT04610801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Spray
Description: Randomized to placebo and Xlear
Study NCT05898828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg flat dose via intravenous infusion on Day 3 of every cycle starting at Cycle 2, for intended duration of 1 year.
Study NCT05270187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (laser therapy)
Description: The Multiwave Locked System Laser will treat both the scan and point application groups. M6 laser equipment (ASA, Arcugnano, Italy) is used in this study in the physiotherapy and rehabilitation department, Faculty of Applied Medical Science, Umm Al-Qura University. It provides synchronized and overlapping continuous and pulsed emissions of Ga-Al-Ar laser emitted in a single hand piece. M6 has a continuous emission of a wavelength of 808 nm with peak power of 1000 mW, mean power of 500mW, spot diameter of 2 cm, and spot area of 3.14 cm2. Pulsed emission has a wavelength of 905 nm, peak power of 25 W, and mean power of 54mW with frequency of 1500 Hz.
Study NCT05270187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Facial massage and facial expression exercises
Description: Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
Study NCT05270187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial massage and facial expression exercises
Description: Facial massage and facial expression exercises will be applied for all patients in the three treatment groups. It includes simple facial expression exercises, active graduated strengthening exercises in front of a mirror (active assisted, freedom, and resisted), proprioceptive neuromuscular facilitation exercises for facial muscles, and resisted exercises for neck muscles. Participants are taught to perform massage and exercises correctly by the physiotherapist. All treatment groups are given instruction to repeat the massage and exercises two times a day for at least 6 weeks. The patient or one of his/her family members will confirm that the participant carries out the massage and exercises at home.
Study NCT05898828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat (5 mg) self-administered on Days -14 and -7 prior to the first vaccination cycle, then entinostat (3 mg) self-administered on Days 1, 8, 15, and 22 of each vaccine cycle (Cycles 1-6). Entinostat continuation for subjects with immunologic response and NED during additional 2 vaccine injections.
Study NCT05898828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide(R) ISA-51 VG Adjuvant
Description: H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
Study NCT05898828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1299 Cell Lysates
Description: H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations). Dose Level 1 (DL1) starting dose is 20 mg lysate protein in 2-2.5 mL Montanide(R) ISA-51 VG adjuvant; lysate concentration will be 8-10 mg/mL. Additional 2 vaccine injections for subjects with immunologic response and NED.
Study NCT05268224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Strip
Description: A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.
Study NCT05388279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS012
Description: JS012, i.v., q3w
Study NCT05388279 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: JS012 combine with chemotherapy
Description: JS012 i.v., q3w combine with chemotherapy
Study NCT05396027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio-guided deep breathing
Description: 2 weeks of audio-guided deep breathing for participants (healthy and physically disabled)
Study NCT05739838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolase ;Low Level Laser
Description: Low Level laser ,940 nm
Study NCT04680000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)
Description: BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
Study NCT04680000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP)
Description: BCBT-CP is the standard of care for behavioral management of acute and chronic pain in the Defense Health Agency Stepped Care Pain Pathway. BCBT-CP is a 7-module, CBT-based intervention for the treatment of acute and chronic pain in the primary care setting. The BCBT-CP manual was developed in a collaboration between the Defense Health Agency and the Department of Veterans Affairs as an intervention tailored for use by Behavioral Health Consultants embedded in Military Health System primary care clinics and Patient Centered Medical Homes. Details on BCBT-CP content can be found in the treatment arm description section of this listing.
Study NCT04910568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 28-day cycle, up to a total of 13 cycles (Arm A), in 28-day cycles Q2W followed by Q4W (Arm B) and in 21 day cycles from C1-C8 Q3W and 28-day cycles from C9 onwards Q4W (Arm C). For Arm A, participants have the option to enter re-treatment after Cycle 13. For Arms B and C, participants can be treated until disease progression or unacceptable toxicity.
Study NCT04910568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Study NCT04910568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally (PO) on a 28-day cycle.
Study NCT04910568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered subcutaneously (SC) on 21 day (C1-8) and 28-day cycles (C9 onwards).
Study NCT04910568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Arm A: Dexamethasone will be administered as a premedication.~Arms B and C: Dexamethasone will be administered via IV or orally at 20 mg as study investigational medicinal product.
Study NCT06397469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediTrain
Description: MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
Study NCT06397469 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Worder
Description: Worder was designed to enhance visual motor and visual spatial skills in individuals of all ages and cognitive abilities. Visual processing is required for all cognitive abilities that involve vision including attention, working memory, and task management. Worder's goal is to improve cognitive function more broadly by developing this critical skill underlying multiple abilities.
Study NCT06369350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6 25 MG
Description: Vitamin B6 25 mg/day will be given for up to 31 days.
Study NCT06369350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6 50 MG
Description: Vitamin B6 50 mg/day will be given for up to 31 days.
Study NCT06369350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B6 100 MG
Description: Vitamin B6 100 mg/day will be given for up to 31 days.
Study NCT06369350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule will be given for up to 31 days.
Study NCT05860699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo made by the same manufacturer to look like the active pills
Study NCT05860699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half dose CBD
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
Study NCT05860699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose CBD
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
Study NCT04680000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCBT-CP Booster
Description: The BCBT-CP Booster is a telephone or videoteleconference-based booster contact designed to extend the benefits of the standard of care BCBT-CP intervention. BCBT-CP Booster contacts are not clinical interventions (i.e., no new clinical content is provided), but are intended to help motivate patients to use BCBT-CP module content, problem-solve BCBT-CP skills practice and offer reminders for future appointments. BCBT-CP Booster content was developed using feedback from focus groups with patients who completed standard BCBT-CP treatment in a military primary care clinic. Details on BCBT-CP Booster contacts can be found in the treatment arm description section of this listing.
Study NCT05284331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: addition of two follow-up visits post infection
Description: Addition of an additional follow-up visit 6 months post infection and one follow-up visit 1 year post infection.~No treatment will be given specifically for this study. The change in medical management will only be modified by the addition of these 2 consultations at 6 months and 1 year post infection
Study NCT05473832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day Cream cosmetic product compared to untreated side
Description: Applied once daily in the morning
Study NCT05473832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Night cream cosmetic product compared to untreated side
Description: Applied once daily in the evening
Study NCT05473832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye cream cosmetic product compared to untreated side
Description: Applied twice daily in the morning and in the evening around the eye area
Study NCT05473832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum cosmetic product compared to untreated side
Description: Applied twice daily in the morning and in the evening
Study NCT06415383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B6 100 MG
Description: Vitamin B6 in for the form of pyridoxal phosphate (PLP)
Study NCT06415383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet containing microcrystalline cellulose
Study NCT05290558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bu Shen Yi Jing Pill
Description: Bu Shen Yi Jing Pill contained Radix Pseudostellaria, Fructus Lycii, Radix Et Rhizoma Salviae, Rhizoma Dioscorea, Semen Plantaginis, Semen Cuscuta, Patriniae Herba, Herba Epimedii, Radix Ophiopogonis, Fructus Rubi, Fructus Corni, Bupleurum roots, Fructus Schisandrae Chinensis, Radix Et Rhizoma Glycyrrhizae.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Study NCT05610254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: On the first trial day healthy volunteers are randomized to receive 30 ml/kg of Ringer's lactate either cold (15°C, 59°F), or at body temperature (37°C, 98.6°F) during a 30-minute interval. After a minimum washout period of 24 hours, subjects are switched to receive infusion at the other aforementioned temperatures.
Study NCT05290558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug
Description: Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Study NCT05382819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRTX-02 Capsule
Description: DYRK-1A Inhibitor
Study NCT05450965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.
Study NCT05382819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT04798053 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: 14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)
Study NCT04798053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: 14-item Perceived Stress Scale (PSS-14), 9-item Patient Health Questionnaire (PHQ-9 questionnaire), State Trait Inventory Anxiety questionnaire (STAI questionnaire), Post-traumatic Stress Disorder Checklist Scale (PCL-S questionnaire)
Study NCT04798053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample and salivary sample
Description: 10 ml whole blood for Peripheral blood and 2 ml saliva sample. Only for 100 cases.
Study NCT05557942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: AV-101 (imatinib) administered via dry powder inhalation
Study NCT04967482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-eluting bead transarterial chemoembolization (DEB-TACE)
Description: The patients will receive DEB-TACE if they choose DEB-TACE as the primary treatment. DC Bead loaded with epirubicin (1 vial of DC Bead loaded with 60 mg of epirubicin) is used for chemoembolization. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. DEB-TACE) for the same patient should be consistent.
Study NCT04967482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional transarterial chemoembolization (cTACE)
Description: The patients will receive cTACE if they choose cTACE as the primary treatment. An emulsion of epirubicin in lipiodol wiil be injected into the tumor feeding artery. Afterwards, microspheres or polyvinyl alcohol particles mixed with contrast agent will be administered intraarterially until arterial flow stasis was achieved. Generally, the dose of lipiodol and epirubicin should not exceed 30 mL and 60 mg for each procedure. During follow-up, TACE will be repeated on demand based on the evaluation of the follow-up laboratory and imaging examination, and the technique method of each TACE procedure (i.e. cTACE) for the same patient should be consistent.
Study NCT05663073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine FDC
Description: Irbesartan/Amlodipine FDC